Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CF101 vs Methotrexate in Early Rheumatoid Arthritis (Phase 3)
2016-003682-26Phase 3Terminated
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piclidenoson in rheumatoid arthritis (RA) (3 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoint: DAS(ESR) low disease activity at Week 12. Started May 2018; status: terminated.
02
Drugs
piclidenoson
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-003682-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003682-26.